



(12) Translation of
European patent specification

(11) NO/EP 2838920 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/24 (2006.01)
C07K 16/28 (2006.01)
C07K 16/46 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.05.08
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.02.01
(86)	European Application Nr.	13726321.6
(86)	European Filing Date	2013.04.16
(87)	The European Application's Publication Date	2015.02.25
(30)	Priority	2012.04.20, US, 201261636302 P 2013.02.25, US, 201361768747 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, US-USA
(72)	Inventor	ALLAN, Barrett, c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288, US-USA BENSCHOP, Robert Jan, c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288, US-USA LU, Jirong, c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288, US-USA
(74)	Agent or Attorney	Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54)	Title	ANTI-BAFF-ANTI-IL-17 BISPECIFIC ANTIBODIES
(56)	References Cited:	WO-A1-2007/070750 WO-A2-2011/141823 US-B2- 7 317 089 AGNÈS DOREAU ET AL: "Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, vol. 10, no. 7, 1 July 2009 (2009-07-01), pages 778-785, XP002661456, ISSN: 1529-2908, DOI: 10.1038/NI.1741 [retrieved on 2009-05-31]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 5 **1.** Bispesifikt antistoff omfattende to første polypeptider og to andre polypeptider, hvori aminosyresekvensen til det første polypeptidet er SEQ ID NO: 1, og aminosyresekvensen til det andre polypeptidet er SEQ ID NO: 2.
- 10 **2.** Det bispesifikke antistoffet ifølge krav 1, hvori der er en intrakjededisulfidbinding mellom cysteinrest 507 ifølge SEQ ID NO: 1 og cysteinrest 707 ifølge SEQ ID NO: 1.
- 15 **3.** Bispesifikt antistoff ifølge krav 1 eller 2 for anvendelse i terapi.
- 20 **4.** Bispesifikt antistoff ifølge krav 1 eller 2 for anvendelse i behandling av systemisk Lupus Erythematosus, lupusnefritt, revmatoid artritt, psoriasis, ankolyserende spondylitt, psoriasisartritt, primært Sjøgrens syndrom eller multippelt myelom.
- 5.** Farmasøytisk sammensetning omfattende et bispesifikt antistoff ifølge krav 1 eller 2 og én eller flere farmasøytisk akseptable bærere, tynnere eller eksipienter.